March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Visual Acuity after 3 Intial Injections of Intravitreal Ranibizumab in the Management of Diabetic Macular Edema
Author Affiliations & Notes
  • Claus Zehetner
    Ophthalmology, Medical University Innsbruck, Innsbruck, Austria
  • Martina T. Kralinger
    Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
  • Gerhard F. Kieselbach
    Ophthalmology, University of Innsbruck, Innsbruck, Austria
  • Footnotes
    Commercial Relationships  Claus Zehetner, None; Martina T. Kralinger, None; Gerhard F. Kieselbach, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 348. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Claus Zehetner, Martina T. Kralinger, Gerhard F. Kieselbach; Visual Acuity after 3 Intial Injections of Intravitreal Ranibizumab in the Management of Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):348.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine change of best corrected visual acuity (BCVA) and anatomic effects of 3 initial intravitreal injections of ranibizumab followed by a pro re nata (PRN) dosing regimen in patients with clinically significant diabetic macular edema (CSME).

Methods: : 15 eyes of 9 patients (mean age, 67,1 years [range, 41-78]) with center-involving CSME were treated with 3 monthly intravitreal injections of 0,5 mg ranibizumab followed by a PRN reinjection regimen. Follow-up in all patients was 6 months.Analysis included the mean change from baseline BCVA and change from baseline mean foveal thickness (FTH) defined as center subfield thickness.Reinjections after week 12 were performed upon signs of disease activity as defined by increase of mean foveal thickness (FTH) determined by SD OCT or loss of best-corrected visual acuity (BCVA).

Results: : The baseline mean BCVA was 0,32±0,22 and the mean FTH was 505±210 μm. Mean HbA1c was 6,4±0,4. At month 3 after 3 intravitreal injections of ranibizumab mean BCVA was 0,38±0,21 (p=1,0) and mean FTH was 333±135 μm (p=0,139). At month 6 mean BCVA was 0,31±0,21 (p=1,0) and mean FTH was 385±143 μm (p=0,019). The mean number of reinjections between month 4 and 6 was 0,43±0,51 resulting in a mean total of 3,43±0,51 injections per study eye. None of the study eyes received more than 1 reinjection and 60% of all study eyes only received the initial 3 injections of ranibizumab.

Conclusions: : In this series a regimen with 3 initial intravitreal injections of ranibizumab followed by PRN reinjections resulted in overall stabilization of BCVA. Despite a favorable morphological response as shown by reduction of mean FTH no statistically significant gain in BCVA could be achieved.This may indicate that a PRN regimen does not prove an equivalent alternative to a fixed-dosing schedule in the treatment of diabetic macular edema.

Keywords: diabetic retinopathy • retina • edema 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.